News | Heart Failure | March 11, 2022

Treating Heart Attacks with a Medium Chain Fatty Acid

Researchers were able to protect against heart attack injury in rat models with octanoic acid, an eight carbon (8C) medium chain fatty acid, as well as a few other metabolites.


March 14, 2022 – A medium-chain fatty acid found in energy drinks might one day help protect against heart attack injuries.

“Heart attacks are still a leading cause of death worldwide, that often come with devastating complications,” said Zhong Wang, Ph.D., an associate professor of cardiac surgery at the University of Michigan Frankel Cardiovascular Center, who is the senior author on a recent preclinical study in eLife. “Better options are needed to reduce injury to the heart after a heart attack, and even improve heart function. In this publication, we target the interplay between energy metabolism and epigenetics mediated by the medium chain fatty acid 8C.”

Wang and colleagues were able to protect against heart attack injury in rat models with octanoic acid, an eight carbon (8C) medium chain fatty acid, as well as a few other metabolites. Those fatty acids produced acetyl-CoA, a building block for energy metabolism, which a stressed heart desperately needs.

The idea is that a physician would administer this therapy to a person once they arrive at the hospital after having a heart attack, to reduce further injury and improve heart function during recovery, he says.

“Understanding the crosstalk between energy metabolism and epigenetics may not only provide an effective target for myocardial infarction, but also have broad implications in other ischemic injury-caused organ damage beyond cardiac diseases,” said Ienglam Lei, Ph.D., from the Frankel CVC’s Department of Cardiac Surgery and the University of Macau in China, who conducted the study’s key experiments.

Wang says the next step would be to test this molecule in large animal models, followed by clinical trials. The research team has been studying the epigenetic regulation of heart attack for more than 10 years.

For more information:

Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation

 

 


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now